Cargando…
Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases
ROCK (Rho kinase) signaling regulates a wide spectrum of fundamental cellular events and is involved in a variety of pathological conditions. It has therefore attracted research interest as a potential therapeutic target for combating various diseases. We showed that inhibition of ROCK enhances cell...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511675/ https://www.ncbi.nlm.nih.gov/pubmed/28751979 http://dx.doi.org/10.1155/2017/2646904 |
_version_ | 1783250380939853824 |
---|---|
author | Okumura, Naoki Kinoshita, Shigeru Koizumi, Noriko |
author_facet | Okumura, Naoki Kinoshita, Shigeru Koizumi, Noriko |
author_sort | Okumura, Naoki |
collection | PubMed |
description | ROCK (Rho kinase) signaling regulates a wide spectrum of fundamental cellular events and is involved in a variety of pathological conditions. It has therefore attracted research interest as a potential therapeutic target for combating various diseases. We showed that inhibition of ROCK enhances cell proliferation, promotes cell adhesion onto a substrate, and suppresses apoptosis of corneal endothelial cells (CECs). In addition, we reported that a ROCK inhibitor enhances wound healing in the corneal endothelium in animal models and in pilot clinical research. We also demonstrated the usefulness of a ROCK inhibitor as an adjunct drug in tissue engineering therapy as it enhances the engraftment of CECs onto recipient corneas. In 2013, we initiated a clinical trial to test the effectiveness of injection of cultured human CECs into the anterior chamber of patients with corneal endothelial decompensation. This paper reviews the accumulating evidence supporting the potency of ROCK inhibitors in clinical use, both as eye drops and as adjunct drugs in cell-based therapies, for the treatment of corneal endothelial decompensation. |
format | Online Article Text |
id | pubmed-5511675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-55116752017-07-27 Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases Okumura, Naoki Kinoshita, Shigeru Koizumi, Noriko J Ophthalmol Review Article ROCK (Rho kinase) signaling regulates a wide spectrum of fundamental cellular events and is involved in a variety of pathological conditions. It has therefore attracted research interest as a potential therapeutic target for combating various diseases. We showed that inhibition of ROCK enhances cell proliferation, promotes cell adhesion onto a substrate, and suppresses apoptosis of corneal endothelial cells (CECs). In addition, we reported that a ROCK inhibitor enhances wound healing in the corneal endothelium in animal models and in pilot clinical research. We also demonstrated the usefulness of a ROCK inhibitor as an adjunct drug in tissue engineering therapy as it enhances the engraftment of CECs onto recipient corneas. In 2013, we initiated a clinical trial to test the effectiveness of injection of cultured human CECs into the anterior chamber of patients with corneal endothelial decompensation. This paper reviews the accumulating evidence supporting the potency of ROCK inhibitors in clinical use, both as eye drops and as adjunct drugs in cell-based therapies, for the treatment of corneal endothelial decompensation. Hindawi 2017 2017-07-02 /pmc/articles/PMC5511675/ /pubmed/28751979 http://dx.doi.org/10.1155/2017/2646904 Text en Copyright © 2017 Naoki Okumura et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Okumura, Naoki Kinoshita, Shigeru Koizumi, Noriko Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases |
title | Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases |
title_full | Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases |
title_fullStr | Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases |
title_full_unstemmed | Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases |
title_short | Application of Rho Kinase Inhibitors for the Treatment of Corneal Endothelial Diseases |
title_sort | application of rho kinase inhibitors for the treatment of corneal endothelial diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511675/ https://www.ncbi.nlm.nih.gov/pubmed/28751979 http://dx.doi.org/10.1155/2017/2646904 |
work_keys_str_mv | AT okumuranaoki applicationofrhokinaseinhibitorsforthetreatmentofcornealendothelialdiseases AT kinoshitashigeru applicationofrhokinaseinhibitorsforthetreatmentofcornealendothelialdiseases AT koizuminoriko applicationofrhokinaseinhibitorsforthetreatmentofcornealendothelialdiseases |